Nonhematologic grade 3 to 4 AEs in AYA patients with ALL treated with C10403 regimen from 2012 to 2020
| Adverse Event . | Grade 3-4 AEs, induction (N = 139, n (%)) . | Grade 3-4 AEs, postremission (N = 101, n (%)) . |
|---|---|---|
| AST elevation | 9 (6) | 20 (20) |
| ALT elevation | 31 (22) | 36 (36) |
| Total bilirubin elevation | 17 (12) | 4 (4) |
| VTE (non-CNS) | 3 (2) | 2 (2) |
| VTE or stroke (CNS) | 6 (4) | 0 (0) |
| Pancreatitis | 5 (4) | 9 (9) |
| Allergic reaction (including anaphylaxis) | 3 (2) | 12 (12) |
| Sepsis | 20 (14) | 17 (17) |
| Adverse Event . | Grade 3-4 AEs, induction (N = 139, n (%)) . | Grade 3-4 AEs, postremission (N = 101, n (%)) . |
|---|---|---|
| AST elevation | 9 (6) | 20 (20) |
| ALT elevation | 31 (22) | 36 (36) |
| Total bilirubin elevation | 17 (12) | 4 (4) |
| VTE (non-CNS) | 3 (2) | 2 (2) |
| VTE or stroke (CNS) | 6 (4) | 0 (0) |
| Pancreatitis | 5 (4) | 9 (9) |
| Allergic reaction (including anaphylaxis) | 3 (2) | 12 (12) |
| Sepsis | 20 (14) | 17 (17) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; VTE, venous thromboembolism.